October 28, 2025

AI Shear Wave Elastography Model for Diagnosing Breast Cancer in BI-RADS 3 or 4 Masses

In a study (INSPiRED 006) reported in the Journal of Clinical Oncology, Cai et al found that an artificial intelligence–guided shear wave elastography (AI-SWE) model provided accuracy similar to exper...

The ASCO Post

October 23, 2025

Thymic Health Associated With ICI Response

New research presented during the European Society for Medical Oncology (ESMO) Congress 2025 showed that thymic health is associated with response to immune checkpoint inhibition in patients with canc...

The ASCO Post

October 22, 2025

Advancing Geriatric Oncology: Where We Have Been and Where We Are Going

The aging population is rapidly growing, with the number of older adults rising steadily each year. In the 1980s, experts predicted a rise in the number of older patients with cancer, yet we were unpr...

The ASCO Post

October 22, 2025

Defying the Odds

In early 2023, I began experiencing serious symptoms that were not easily explained away, including deep vein thrombosis in my left leg, extreme weight loss, bruising, wheezing, and shortness of breat...

The ASCO Post

October 22, 2025

Biomarker-Driven Apalutamide Therapy for Patients With Recurrent Prostate Cancer

Use of PAM50 subtyping allowed clinicians to determine which patients with recurrent prostate cancer were most likely to benefit from the addition of apalutamide hormonal therapy to salvage radiothera...

The ASCO Post

October 21, 2025

Localized PI3K-Altered Colorectal Cancer: Does Low-Dose Aspirin Reduce the Risk of Recurrence?

In a Scandinavian trial (ALASCCA) reported in the New England Journal of Medicine, Martling et al found that low-dose aspirin reduced the risk of disease recurrence vs placebo in patients with PI3K-al...

The ASCO Post

October 20, 2025

Updated ASTRO-ASCO-SSO PMRT Guideline: Key Changes and Clinical Implications

New joint clinical practice guidelines from ASTRO, ASCO, and SSO, published in the Journal of Clinical Oncology, provide the most comprehensive update in a decade on postmastectomy radiation therapy (PMRT) for breast cancer.

Baptist Health South Florida

October 20, 2025

Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer

The Dana-Farber-co-led phase 3 IMvigor011 trial results show that periodic ctDNA screening after surgery can help guide a decision to begin adjuvant immunotherapy.

Dana-Farber

October 19, 2025

ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.

Dana-Farber